Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma

Ernesto Crisafulli, Andrea Zanini, Giovanna Pisi, Patrizia Pignatti, Gianluigi Poli, Mario Scuri, Alfredo Chetta

Research output: Contribution to journalArticle

Abstract

Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique, this influences drug delivery and distribution along the bronchial tree, including the most peripheral airways. The fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) is the only extrafine formulation available in pressurized metered dose inhaler (pMDI) and in dry powder inhaler (DPI). Here, we focus on the recent significant advances regarding BDP/FF fixed combination for the treatment of asthma.

Original languageEnglish
Pages (from-to)481-490
Number of pages10
JournalExpert Review of Respiratory Medicine
Volume10
Issue number5
DOIs
Publication statusPublished - May 3 2016

Keywords

  • Asthma
  • beclometasone dipropionate/formoterol fumarate
  • DPI
  • extrafine
  • fixed combination
  • inflammation
  • pMDI
  • small airways

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma'. Together they form a unique fingerprint.

  • Cite this